Important note: Information in this article was accurate in July 2005. The state of the art may have changed since the publication date.
 |
HIV Treatment Bulletin - Vol. 6, No. 7, July 2005
Simon Collins, HIV i-Base
Last year at the Bangkok IAS conference an Italian E-184V study, of 60 patients with CD4 counts >500 cells/mm3 who had the M184V mutation on HAART, and who wanted to stop treatment, reported lower CD4 reductions and additional clinical benefits in patients who maintained 3TC monotherapy, compared to patients who interrupted all their drugs.
At the Resistance Workshop, Nicola Gianotti and colleagues an analysis of viral replicative capacity from this study. Replicative capacity (RC) from the first 31 consecutive patients in the study was measured as p24Ag productivity from recombinant clones after four days in culture. Median replicative capacity ratio was calculated as RC at week 24 divided by RC at study baseline; this was 11.42 (IQR 2.4-57.1) in the treatment interruption group and 1.14 (IQR 1.00-1.28) in the 3TC monotherapy group (p=0.0006).
Protocol defined failure in the study was a CD4 drop to below 350 cells/mm3. In this analysis patients with protocol failure prior to 24 weeks had greater RC recovery compared to those without early failure. RC ratio also correlated with CD4 and CD4% decreases at week 24 (r=-0.46, p=0.01 and r=-0.55, p=0.001, respectively); but not with baseline CD4, CD4%, viral load, 24-week increase in viral load, or 48-week changes in CD4 and viral load.
RC recovery was consistent with reduction in resistance in protease and RT mutation and with the outgrowth of wild-type virus at position 184, although statistically analysis for this is still ongoing.
Ref: Gianotti E, Menzo S, Danise A et al. E-184V study: immunological and virological correlates of HIV-1 replicative capacity. Antivir Ther. 10, Suppl 1:S175 (abstract no. 160).
050710
IB050607-05
©2005. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, Bridgestone / Firestone Trust, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.
